VALNEVA SE ADR

NASDAQ: VALN (Valneva SE)

最近更新时间: 1小时之前

6.37

-0.03 (-0.47%)

前收盘价格 6.40
收盘价格 6.38
成交量 2,279
平均成交量 (3个月) 79,478
市值 545,150,272
价格/销量 (P/S) 2.67
股市价格/股市净资产 (P/B) 2.87
52周波幅
3.62 (-43%) — 9.50 (49%)
利润日期 12 Aug 2025
营业毛利率 -7.22%
营业利益率 (TTM) -38.61%
稀释每股收益 (EPS TTM) -0.180
季度收入增长率 (YOY) 26.40%
总债务/股东权益 (D/E MRQ) 119.34%
流动比率 (MRQ) 2.61
营业现金流 (OCF TTM) -67.22 M
杠杆自由现金流 (LFCF TTM) -83.02 M
资产报酬率 (ROA TTM) -10.03%
股东权益报酬率 (ROE TTM) -7.91%

市场趋势

短期 中期
行业 Biotechnology (US) 看跌 看跌
Biotechnology (全球的) 看跌 看跌
股票 Valneva SE 看跌 看跌

AIStockmoo 评分

0.8
分析师共识 3.0
内部交易活动 NA
价格波动 -2.0
技术平均移动指标 2.5
技术振荡指标 -0.5
平均 0.75

相关股票

股票 市值 DY P/E(TTM) P/B
VALN 545 M - - 2.87
RVMD 7 B - - 3.31
VRNA 6 B - - 27.21
AKRO 4 B - - 3.41
CRNX 3 B - - 2.12
KYMR 2 B - - 2.38

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.

部门 Healthcare
行业 Biotechnology
投资方式 Small Core
机构持股比例 0.87%

所有权

姓名 日期 持有股份
General American Investors Co Inc 31 Dec 2024 354,361
Ironwood Investment Management Llc 31 Dec 2024 25,022
Vsm Wealth Advisory, Llc 31 Dec 2024 1,000
52周波幅
3.62 (-43%) — 9.50 (49%)
目标价格波幅
14.00 (119%) — 17.00 (166%)
17.00 (HC Wainwright & Co., 166.88%) 购买
15.50 (143.33%)
14.00 (Guggenheim, 119.78%) 购买
平均值 15.50 (143.33%)
总计 2 购买
平均价格@调整类型 6.72
公司 日期 目标价格 调整类型 价格@调整类型
Guggenheim 08 May 2025 14.00 (119.78%) 购买 6.38
24 Mar 2025 15.00 (135.48%) 购买 7.43
HC Wainwright & Co. 15 Apr 2025 17.00 (166.88%) 购买 7.05
09 Apr 2025 17.00 (166.88%) 购买 6.77
日期 类型 细节
12 May 2025 公告 Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
12 May 2025 公告 Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
07 May 2025 公告 Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates
07 May 2025 公告 Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates
07 May 2025 公告 VALNEVA Declaration of shares and voting rights: April 30, 2025
07 May 2025 公告 Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly
07 May 2025 公告 Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly
26 Apr 2025 公告 Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities
26 Apr 2025 公告 Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities
18 Apr 2025 公告 Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers
18 Apr 2025 公告 Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers
16 Apr 2025 公告 Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®
16 Apr 2025 公告 Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®
14 Apr 2025 公告 Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country
14 Apr 2025 公告 Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country
09 Apr 2025 公告 Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
09 Apr 2025 公告 Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
03 Apr 2025 公告 Valneva SE Shareholding Declaration - March 2025
01 Apr 2025 公告 Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above
01 Apr 2025 公告 Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above
31 Mar 2025 公告 Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA
31 Mar 2025 公告 Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA
26 Mar 2025 公告 Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program
26 Mar 2025 公告 Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program
25 Mar 2025 公告 Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F
25 Mar 2025 公告 Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F
24 Mar 2025 公告 Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion
24 Mar 2025 公告 Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion
20 Mar 2025 公告 Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook
20 Mar 2025 公告 Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook
05 Mar 2025 公告 VALNEVA Declaration of shares and voting rights: February 28, 2025
03 Mar 2025 公告 Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
03 Mar 2025 公告 Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票